Drug Shortage Report for TEVA-SALBUTAMOL HFA
| Report ID | 105599 |
| Drug Identification Number | 02326450 |
| Brand name | TEVA-SALBUTAMOL HFA |
| Common or Proper name | SALBUTAMOL 100MCG HFA INHALER |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | SALBUTAMOL |
| Strength(s) | 100MCG |
| Dosage form(s) | METERED-DOSE AEROSOL |
| Route of administration | INHALATION |
| Packaging size | 200 dose |
| ATC code | R03AC |
| ATC description | ADRENERGICS, INHALANTS |
| Reason for shortage | Other (Please describe in comments) |
| Anticipated start date | |
| Actual start date | 2020-02-07 |
| Estimated end date | 2020-07-31 |
| Actual end date | 2020-07-29 |
| Shortage status | Resolved |
| Updated date | 2020-07-30 |
| Company comments | Teva Allocating to 70% of the generic market. Increased demand experienced. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2020-02-07 | English | Compare |